Lynch syndrome (LS) is caused by mutations in mismatch repair genes and is characterized by a high cumulative risk for the development of mainly colorectal carcinoma and endometrial carcinoma. Early detection of LS is important since surveillance can reduce morbidity and mortality. However, the diagnosis of LS is complicated by the absence of a pre-morbid phenotype and germline mutation analysis is expensive and time consuming. Therefore it is standard practice to precede germline mutation analysis by a molecular diagnostic work-up of tumours, guided by clinical and pathological criteria, to select patients for germline mutation analysis. In this review we address these molecular analyses, the central role for the pathologist in the selection of patients for germline diagnostics of LS, as well as the molecular basis of LS.

Additional Metadata
Keywords BRAF mutation analysis, Immunohistochemistry, Lynch syndrome, MLH1 promoter methylation assay, MSI analysis, Mismatch repair genes, Molecular pathology, Review
Persistent URL dx.doi.org/10.1111/j.1582-4934.2009.00977.x, hdl.handle.net/1765/19809
Citation
van Lier, M.G.F., Wagner, A., van Leerdam, M.E., Biermann-Pauls, K., Kuipers, E.J., Steyerberg, E.W., … Dinjens, W.N.M.. (2010). A review on the molecular diagnostics of Lynch syndrome: A central role for the pathology laboratory. Journal of Cellular and Molecular Medicine: a journal of translational medicine, 14(1-2), 181–197. doi:10.1111/j.1582-4934.2009.00977.x